Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables (2016 - 2025)

Enanta Pharmaceuticals' Change in Receivables history spans 14 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 50.28% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $775000.0, up 270.33%, while the annual FY2025 figure was $236000.0, 111.99% up from the prior year.
  • Change in Receivables reached $1.6 million in Q4 2025 per ENTA's latest filing, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $4.1 million in Q4 2021 to a low of -$11.6 million in Q1 2021.
  • Average Change in Receivables over 5 years is -$1.2 million, with a median of $591500.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: crashed 1325.03% in 2023, then soared 343.08% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $4.1 million in 2021, then crashed by 44.33% to $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then soared by 343.08% to $1.1 million in 2024, then soared by 50.28% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Change in Receivables are $1.6 million (Q4 2025), -$1.5 million (Q3 2025), and $1.5 million (Q2 2025).